Advanced search
Publication Cover
Expert Opinion on Investigational Drugs Volume 23, 2014 - Issue 1
Submit an article Journal homepage
499
Views
23
CrossRef citations to date
0
Altmetric
Drug Evaluations

Development of mavoglurant and its potential for the treatment of fragile X syndrome

Baltazar Gomez-MancillaNovartis Institutes for BioMedical Research Basel, Forum 1, Novartis Campus, CH-4056 Basel, Switzerland+41 61 324 0164; +41 61 324 8913; [email protected]
, MD PhD,
Elizabeth Berry-KravisRush University Medical Center, Departments of Pediatrics, Neurological Sciences, and Biochemistry, Chicago, IL 60612, USA
, MD PhD,
Randi HagermanM.I.N.D. Institute and Department of Pediatrics, UC Davis Health System, Sacramento, CA 95817, USA
, MD,
Florian von RaisonNovartis Pharma AG, Neuroscience Development, CH-4056 Basel, Switzerland
, MD,
George ApostolNovartis Pharma AG, Neuroscience Development, CH-4056 Basel, Switzerland
, MD MS,
Mike UferNovartis Institutes for BioMedical Research Basel, Forum 1, Novartis Campus, CH-4056 Basel, Switzerland+41 61 324 0164; +41 61 324 8913; [email protected]
, MD PhD,
Fabrizio GaspariniNovartis Institutes for BioMedical Research Basel, Forum 1, Novartis Campus, CH-4056 Basel, Switzerland+41 61 324 0164; +41 61 324 8913; [email protected]
&
Sébastien JacquemontService de Génétique Médicale, Centre Hospitalier Universitaire Vaudois, 2 Ave Pierre Decker, 1011 Lausanne, Switzerland
, MD show all
Pages 125-134 | Published online: 20 Nov 2013

Citations (23)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (4)

Ali Jazayeri & Fiona Marshall. (2015) Implications of metabotropic glutamate receptor structures for drug discovery in neurotherapeutics. Expert Review of Neurotherapeutics 15:2, pages 123-125.
Read now
Sylvain Celanire, Iyassu Sebhat, Juergen Wichmann, Stanislas Mayer, Stephan Schann & Silvia Gatti. (2015) Novel metabotropic glutamate receptor 2/3 antagonists and their therapeutic applications: a patent review (2005 – present). Expert Opinion on Therapeutic Patents 25:1, pages 69-90.
Read now
Katherine E Schwetye & David H Gutmann. (2014) Cognitive and behavioral problems in children with neurofibromatosis type 1: challenges and future directions. Expert Review of Neurotherapeutics 14:10, pages 1139-1152.
Read now
Dmitry Petrov, Ignacio Pedros, Maria Luisa de Lemos, Mercè Pallàs, Anna Maria Canudas, Alberto Lazarowski, Carlos Beas-Zarate, Carme Auladell, Jaume Folch & Antoni Camins. (2014) Mavoglurant as a treatment for Parkinson’s disease. Expert Opinion on Investigational Drugs 23:8, pages 1165-1179.
Read now

Articles from other publishers (19)

Lamiaa Hamie, Edward Eid, Joanna Khalil, Rayah Touma Sawaya, Ossama Abbas & Mazen Kurban. (2022) Genodermatoses with behavioural sequelae. Postgraduate Medical Journal 98:1164, pages 799-810.
Crossref
Johannes Streffer, Valerie Treyer, Alfred Buck, Simon M. Ametamey, Milen Blagoev, Ralph P Maguire, Aurélie Gautier, Yves P. Auberson, Mark E. Schmidt, Ivan-Toma Vranesic, Baltazar Gomez-Mancilla & Fabrizio Gasparini. (2021) Regional brain mGlu5 receptor occupancy following single oral doses of mavoglurant as measured by [11C]-ABP688 PET imaging in healthy volunteers. NeuroImage 230, pages 117785.
Crossref
Michael Telias. (2020) Pharmacological Treatments for Fragile X Syndrome Based on Synaptic Dysfunction. Current Pharmaceutical Design 25:41, pages 4394-4404.
Crossref
Youwen Xu & Zizhong Li. (2019) Imaging metabotropic glutamate receptor system: Application of positron emission tomography technology in drug development. Medicinal Research Reviews 39:5, pages 1892-1922.
Crossref
Pamela R. Westmark, Andrzej Dekundy, Andreas Gravius, Wojciech Danysz & Cara J. Westmark. (2018) Rescue of Fmr1 phenotypes with mGluR5 inhibitors: MRZ-8456 versus AFQ-056. Neurobiology of Disease 119, pages 190-198.
Crossref
Hayley P. Drozd, Sotirios F. Karathanasis, Andrei I. Molosh, Jodi L. Lukkes, D. Wade Clapp & Anantha Shekhar. 2018. Genetic Models and Molecular Pathways Underlying Autism Spectrum Disorders. Genetic Models and Molecular Pathways Underlying Autism Spectrum Disorders 113 158 .
Kaizad MunshiKatherine PawlowskiJoseph Gonzalez-HeydrichJonathan D. Picker. (2017) Review of Salient Investigational Drugs for the Treatment of Fragile X Syndrome. Journal of Child and Adolescent Psychopharmacology 27:10, pages 850-863.
Crossref
Christina M. Harkins, Kelli C. Dominick, Logan K. Wink, Ernest V. Pedapati, Rebecca C. Shaffer, Sarah E. Fitzpatrick, Matthew H. Davenport, John A. Sweeney & Craig A. Erickson. (2017) Challenges in Conducting Clinical Trials for Pharmacotherapies in Fragile X Syndrome: Lessons Learned. Pharmaceutical Medicine 31:4, pages 235-244.
Crossref
Frank Haessler, Franziska Gaese, Michael Huss, Christoph Kretschmar, Marc Brinkman, Helmut Peters, Samuel Elstner, Michael Colla & David Pittrow. (2016) Characterization, treatment patterns, and patient-related outcomes of patients with Fragile X syndrome in Germany: final results of the observational EXPLAIN-FXS study. BMC Psychiatry 16:1.
Crossref
Laura Greiss Hess, Sarah E. Fitzpatrick, Danh V. Nguyen, Yanjun Chen, Kimberly N. Gaul, Andrea Schneider, Kerrie Lemons Chitwood, Marwa Abd Al Azaim Eldeeb, Jonathan Polussa, David Hessl, Susan Rivera & Randi J. Hagerman. (2016) A Randomized, Double-Blind, Placebo-Controlled Trial of Low-Dose Sertraline in Young Children With Fragile X Syndrome. Journal of Developmental & Behavioral Pediatrics 37:8, pages 619-628.
Crossref
M. Raspa, P. Sacco, S.D. Candrilli, E. Bishop & J. Petrillo. (2016) Validity of a condition specific outcome measure for fragile X syndrome: the Aberrant Behaviour Checklist-utility index. Journal of Intellectual Disability Research 60:9, pages 844-855.
Crossref
Thierry Wendling, Swati Dumitras, Kayode Ogungbenro & Leon Aarons. (2015) Application of a Bayesian approach to physiological modelling of mavoglurant population pharmacokinetics. Journal of Pharmacokinetics and Pharmacodynamics 42:6, pages 639-657.
Crossref
Joel D. Richter, Gary J. Bassell & Eric Klann. (2015) Dysregulation and restoration of translational homeostasis in fragile X syndrome. Nature Reviews Neuroscience 16:10, pages 595-605.
Crossref
Kirstie A Bennett, Andrew S Doré, John A Christopher, Dahlia R Weiss & Fiona H Marshall. (2015) Structures of mGluRs shed light on the challenges of drug development of allosteric modulators. Current Opinion in Pharmacology 20, pages 1-7.
Crossref
Xiaowei Jin & Li Chen. (2015) Fragile X syndrome as a rare disease in China – Therapeutic challenges and opportunities. Intractable & Rare Diseases Research 4:1, pages 39-48.
Crossref
Yuh-Jiin I. Jong, Ismail Sergin, Carolyn A. Purgert & Karen L. O’Malley. (2014) Location-Dependent Signaling of the Group 1 Metabotropic Glutamate Receptor mGlu5. Molecular Pharmacology 86:6, pages 774-785.
Crossref
Ana Rita Santos, Alexandros K. Kanellopoulos & Claudia Bagni. (2014) Learning and behavioral deficits associated with the absence of the fragile X mental retardation protein: what a fly and mouse model can teach us. Learning & Memory 21:10, pages 543-555.
Crossref
Christina Mølck, Kasper Harpsøe, David E. Gloriam, Jesper M. Mathiesen, Søren M. Nielsen & Hans Bräuner-Osborne. (2014) mGluR5: Exploration of Orthosteric and Allosteric Ligand Binding Pockets and Their Applications to Drug Discovery. Neurochemical Research 39:10, pages 1862-1875.
Crossref
Arnau Busquets-Garcia, Rafael Maldonado & Andrés Ozaita. (2014) New insights into the molecular pathophysiology of fragile X syndrome and therapeutic perspectives from the animal model. The International Journal of Biochemistry & Cell Biology 53, pages 121-126.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.